Novel Treatment Appears to Show Benefit in ALS
(MedPage Today) -- DENVER -- A novel treatment candidate for amyotrophic lateral sclerosis (ALS) met its primary safety and secondary endpoints in the phase IIb PARADIGM trial.
ALS patients treated with PrimeC -- a formulation of two FDA-approved... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 19, 2024 Category: Neurology Source Type: news
Why an ALS Drug Was Pulled From the Market
(MedPage Today) -- DENVER -- Topline data presented here showed why Amylyx Pharmaceuticals decided to remove its amyotrophic lateral sclerosis (ALS) drug sodium phenylbutyrate and taurursodiol (Relyvrio), also known as AMX0035, from the market... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 17, 2024 Category: American Health Source Type: news
Chemicals Stored in Your Garage Could Raise Odds for ALS
MONDAY, April 15, 2024 -- Volatile and toxic chemicals commonly stored in garages can increase the risk of amyotrophic lateral sclerosis (ALS).
Gasoline or kerosene, gas-powered equipment and lawn care chemicals represented the top three risk... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 15, 2024 Category: General Medicine Source Type: news
ALS Therapy to Be Pulled From the Market, Drugmaker Says
(MedPage Today) -- Amylyx Pharmaceuticals announced Thursday that it's removing its amyotrophic lateral sclerosis (ALS) drug sodium phenylbutyrate and taurursodiol (Relyvrio), also known as AMX0035, from U.S. and Canadian markets.
The company... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 4, 2024 Category: American Health Source Type: news
Drug maker pulls failed ALS treatment from market in rare move
Semafor Signals Supported by Insights from The Associated Press, The Washington Post, and Politico The News The maker of a failed drug meant to treat amyotrophic lateral sclerosis (ALS) said Thursday it will voluntarily pull the treatment from the market, a rare move for a pharmaceutical company.…#politico #news #als #lougehrigs #fda #alsassociation (Source: Reuters: Health)
Source: Reuters: Health - April 4, 2024 Category: Consumer Health News Source Type: news
ALS drug pulled from market in Canada, U.S. after failing late-stage clinical trial
Amylyx Pharmaceuticals has announced it will withdraw its amyotrophic lateral sclerosis (ALS) drug from the market in Canada and the U.S. following its failure in a late-stage clinical trial. (Source: CBC | Health)
Source: CBC | Health - April 4, 2024 Category: Consumer Health News Tags: News/Health Source Type: news
A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says
Results of a large clinical trial found the treatment did not work any better than a placebo. (Source: NYT Health)
Source: NYT Health - April 4, 2024 Category: Consumer Health News Authors: Pam Belluck Tags: Clinical Trials Drugs (Pharmaceuticals) Amyotrophic Lateral Sclerosis Suits and Litigation (Civil) Brain your-feed-science your-feed-healthcare Food and Drug Administration Source Type: news
Some Recreational Activities Might Up Amyotrophic Lateral Sclerosis Risk
TUESDAY, March 26, 2024 -- Recreational activities — including golfing, gardening or yard work, woodworking and hunting — may be associated with an increased risk of developing amyotrophic lateral sclerosis (ALS), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 26, 2024 Category: Pharmaceuticals Source Type: news
EverythingALS Launches the Vision 2030 AI Hub: Charting the Path to an ALS Cure and Advancing Neurodegenerative Disease Research
SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- EverythingALS, a leading force in the fight against Amyotrophic Lateral Sclerosis (ALS), today announced the Vision 2030 AI Hub, an innovative platform that will accelerate ALS research using Artificial Intelligence (AI), Machine Learning (ML), and…#everythingals #als #machinelearning #indunavar #billnuti #ncr #vision2030 #mit #ernestfraenkel #meritcudkowicz (Source: Reuters: Health)
Source: Reuters: Health - March 12, 2024 Category: Consumer Health News Source Type: news
ALS Drug Relyvrio May Be Pulled From Market
MONDAY, March 11, 2024 -- Amylyx Pharmaceuticals announced Friday that the controversial amyotrophic lateral sclerosis (ALS) drug Relyvrio has failed to help patients in a large follow-up study; however, the company has stopped short of saying it... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2024 Category: Pharmaceuticals Source Type: news
Insurer Delays and Denials Hamper Patients Seeking At-Home Ventilators
(MedPage Today) -- Amyotrophic lateral sclerosis (ALS) took away Grace Armant's ability to speak, but the 84-year-old still has plenty to say about her insurance.
UnitedHealthcare has rejected several requests from her doctors for coverage of... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 11, 2024 Category: American Health Source Type: news
A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market
Leaders of the treatment ’s manufacturer, Amylyx, said they would announce their plans for it within eight weeks. (Source: NYT Health)
Source: NYT Health - March 8, 2024 Category: Consumer Health News Authors: Pam Belluck Tags: Clinical Trials Amyotrophic Lateral Sclerosis Drugs (Pharmaceuticals) Amylyx Pharmaceuticals Inc Food and Drug Administration Cohen, Joshua B Klee, Justin United States your-feed-healthcare Source Type: news
EMA Approves Two Therapies for Rare Genetic Diseases EMA Approves Two Therapies for Rare Genetic Diseases
Treatments for amyotrophic lateral sclerosis and paroxysmal nocturnal hemoglobinuria have been given marketing authorization by the European Medicines Agency.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 23, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Study Confirms Link Between Smoking and ALS
TUESDAY, Jan. 30, 2024 -- New research is helping confirm smoking as a risk factor for the devastating brain illness amyotrophic lateral sclerosis (ALS).
ALS affects roughly 31,000 Americans each year, with about 5,000 new cases diagnosed annually,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 30, 2024 Category: General Medicine Source Type: news
Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication
Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024- -Marks the first IND for Aruna's platform with plans to expand AB126, an unmodified exosome derived from proprietary neural stem cells, to other neurological indications including amyotrophic lateral sclerosis-…#gmp #boston #athens #arunabioinc #fda #ab126 #stevenstice #phd #cns #seansavitzmd (Source: Reuters: Health)
Source: Reuters: Health - January 16, 2024 Category: Consumer Health News Source Type: news
